MSN Labs enters into licence deal with DRDE for Covid drug 2-DG

Drug firm MSN Laboratories on Friday said it has entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-d-glucose (2-DG), used for the treatment of COVID-19. Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India for emergency use as adjunct therapy in moderate to severe Covid patients, MSN Labs said in a statement.